ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Boehringer options Autifony compounds

by Lisa M. Jarvis
January 1, 2018 | APPEARED IN VOLUME 96, ISSUE 1

Boehringer Ingelheim will pay nearly $30 million up front for the option to acquire Autifony Therapeutics’ voltage-gated potassium channel modulator platform. The pact includes AUT00206, currently in a Phase II study to treat schizophrenia. Autifony was spun off of GlaxoSmithKline in 2011 to develop modulators of Kv3 voltage-gated potassium channels, which allow neurons to fire with precision. Its compounds are also being studied as treatments for hearing disorders and rare neurological disorders such as fragile X syndrome.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment